Diabetes Treatment

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Diabetes care routinely focuses on the heart, feet, eyes, liver and kidneys. The mouth, however, is frequently overlooked, even though oral health both affects and is affected by diabetes

With diabetes impacting families across the globe, World Diabetes Day 2025 focuses on raising awareness, encouraging prevention and strengthening access to timely care.

Abbott, a global healthcare company, on Thursday announced the launch of a new and advanced formulation of 'Ensure Diabetes Care' in India. Building on over 30 years of pioneering scientific nutrition and supported by more than 60 clinical trials, the innovation empowers people with diabetes to live a better life, it said in a statement. The new design features a triple care system with vital nutrients, including four times higher myo-inositol compared to the previous formulation, a low glycaemic index carbohydrate blend, which is designed to help minimise blood sugar spikes. Combined with high protein and high fibre, the nutrients work together to support blood sugar control, help reduce cholesterol, and aid in weight management, the US-based healthcare company said. The formulation also helps preserve lean muscle during weight loss, while significantly reducing overall body fat, including visceral fat -- stored deep in the belly around organs like the liver and pancreas -- which is

About 44 per cent of the world's diabetics were undiagnosed in 2023, while underdiagnosis and sub-optimal management of glycaemic index continue to pose major challenges in low- and middle-income countries, according to an analysis. Estimates published in The Lancet Diabetes and Endocrinology journal show that 43.6 per cent of India's diabetic population were diagnosed with the condition in 2023, an increase of about 14 per cent in diagnosis rates seen in 2000. Over 97 per cent of those diagnosed were under treatment in 2023, an international team of researchers forming the 'Global Burden of Disease' (GBD) study found. More than 55 per cent of people aged 15 and above around the world were diagnosed with diabetes, the analysis of data collected during 2000-2023 from across 204 countries and territories revealed. "By 2050, 1.3 billion people are expected to be living with diabetes, and if nearly half don't know they have a serious and potentially deadly health condition, it could ..

About a fifth of those aged 45 and above were living with diabetes in 2019, with two in every five possibly unaware of their condition, according to data from a study among India's ageing adults. Findings published in The Lancet Global Health also suggest that as the country's population rapidly ages, diabetes cases among the middle-aged and older adults will increase, even if increase in prevalence of the condition in age-specific groups can be arrested, authors said. Researchers, including those from the International Institute for Population Sciences, Mumbai, and US, also found that 46 per cent of those aware of their diabetes regained a control over blood sugar levels, while around 60 per cent were able to control their blood pressure the same year. Six per cent were taking a lipid-lowering medication to reduce the risk of cardiovascular disease, the team said. The 'Longitudinal Aging Study in India' (LASI), which surveyed about 60,000 adults aged 45 and above during 2017-2019

Jamun seed powder contains jamboline and jambosine that help regulate blood sugar, support pancreatic function, and may aid in diabetes prevention if used correctly

A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope for long-term freedom from injections

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with semaglutide formulations being a focal point

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

In 2022, there were around 828 million people aged 18 years and older with type 1 and type 2 diabetes worldwide, the study found

Adipose tissue cells from the patient were reprogrammed into stem cells, converted to islet cells, and transplanted back, eliminating the risk of immune rejection as they were from her own body

Also known as latent autoimmune diabetes in adults (LADA), type 1.5 diabetes has features of both type 1 and type 2 diabetes

A 59-year-old man with type 2 diabetes received an innovative cell transplant and has been insulin-free and off medication for 33 months, offering hope to other diabetes patients

The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

The findings, published in JAMA Network Open, showed that men were more likely to develop diabetes than women

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India